CYP-based biomarkers are broadly categorized as follows: (i) Genetic biomarkers: Variants or polymorphisms in CYP genes have been linked to a predisposition to neurological disorders, supporting early risk assessment and personalized treatment strategies. This evidence concerns the gene PPIG and nervous system disorder.